

# Svenja Meierjohann

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6730313/svenja-meierjohann-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28 papers	850 citations	17 h-index	29 g-index
29 ext. papers	1,030 ext. citations	7.5 avg, IF	4.37 L-index

#	Paper	IF	Citations
28	Subgroup-Independent Mapping of Renal Cell Carcinoma-Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 621278	5.3	17
27	NRF2 Enables EGFR Signaling in Melanoma Cells. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	6
26	NRF2-dependent stress defense in tumor antioxidant control and immune evasion. <i>Pigment Cell and Melanoma Research</i> , <b>2021</b> , 34, 268-279	4.5	7
25	Effect of stress-induced polyploidy on melanoma reprogramming and therapy resistance. <i>Seminars in Cancer Biology</i> , <b>2021</b> ,	12.7	1
24	Emerging aspects in the regulation of ferroptosis. <i>Biochemical Society Transactions</i> , <b>2020</b> , 48, 2253-2259	5.1	6
23	The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression. <i>Oncogene</i> , <b>2020</b> , 39, 6841-6855	9.2	22
22	The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas. <i>Cancer</i> , <b>2019</b> , 125, 586-600	6.4	13
21	Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma. <i>Journal of Investigative Dermatology</i> , <b>2018</b> , 138, 1573-1581	4.3	21
20	Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma. <i>Cancer Cell</i> , <b>2018</b> , 33, 322-336.e8	24.3	64
19	RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas. <i>Oncogene</i> , <b>2018</b> , 37, 6136-6151	9.2	49
18	Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors. <i>Melanoma Research</i> , <b>2018</b> , 28, 465-468	3.3	3
17	Crosstalk signaling in targeted melanoma therapy. <i>Cancer and Metastasis Reviews</i> , <b>2017</b> , 36, 23-33	9.6	14
16	BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines. <i>Cancer Letters</i> , <b>2017</b> , 404, 70-78	9.9	6
15	Peroxiredoxin 6 triggers melanoma cell growth by increasing arachidonic acid-dependent lipid signalling. <i>Biochemical Journal</i> , <b>2015</b> , 471, 267-79	3.8	25
14	Hypoxia-independent drivers of melanoma angiogenesis. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 102	5.3	13
13	Oxidative stress in melanocyte senescence and melanoma transformation. <i>European Journal of Cell Biology</i> , <b>2014</b> , 93, 36-41	6.1	43
12	The MAPK pathway as an apoptosis enhancer in melanoma. <i>Oncotarget</i> , <b>2014</b> , 5, 5040-53	3.3	30

11	Tumor angiogenesis is caused by single melanoma cells in a manner dependent on reactive oxygen species and NF- $\kappa$ B. <i>Journal of Cell Science</i> , <b>2013</b> , 126, 3862-72	5.3	21
10	Vemurafenib induces senescence features in melanoma cells. <i>Journal of Investigative Dermatology</i> , <b>2013</b> , 133, 1601-9	4.3	80
9	Inducible and repressable oncogene-addicted hepatocellular carcinoma in Tet-on xmrk transgenic zebrafish. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 419-25	13.4	90
8	ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma. <i>International Journal of Cancer</i> , <b>2012</b> , 130, 2801-11	7.5	26
7	Conserved expression signatures between medaka and human pigment cell tumors. <i>PLoS ONE</i> , <b>2012</b> , 7, e37880	3.7	30
6	A mutated EGFR is sufficient to induce malignant melanoma with genetic background-dependent histopathologies. <i>Journal of Investigative Dermatology</i> , <b>2010</b> , 130, 249-58	4.3	68
5	MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation. <i>Molecular Cancer</i> , <b>2010</b> , 9, 201	42.1	43
4	Quantitative differential proteome analysis in an animal model for human melanoma. <i>Journal of Proteome Research</i> , <b>2009</b> , 8, 1818-27	5.6	20
3	From Mendelian to molecular genetics: the Xiphophorus melanoma model. <i>Trends in Genetics</i> , <b>2006</b> , 22, 654-61	8.5	93
2	The oncogenic epidermal growth factor receptor variant Xiphophorus melanoma receptor kinase induces motility in melanocytes by modulation of focal adhesions. <i>Cancer Research</i> , <b>2006</b> , 66, 3145-52	10.1	26
1	A structural model of the extracellular domain of the oncogenic EGFR variant Xmrk. <i>Zebrafish</i> , <b>2006</b> , 3, 359-69	2	13